ReviewNeurosurgical focus2012
Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology.
Review in Neurosurgical focus, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 143 citations in OpenAlex.
- Locoregional Delivery of miRNAs for Glioblastoma Treatment: A Systematic Review of Advances in Delivery Systems.Pharmaceutics · 2026Review
- Old Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025Review
- Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group.Molecular therapy. Nucleic acids · 2025Review
- Pediatric neuro-oncology: Highlights of the last quarter-century.Neoplasia (New York, N.Y.) · 2025Review
- A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer's disease.Heliyon · 2024Review
- Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy.Translational neurodegeneration · 2024Review
- Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics.International journal of molecular sciences · 2024Review
- Advancements in strategies for overcoming the blood-brain barrier to deliver brain-targeted drugs.Frontiers in aging neuroscience · 2024Review
- Protocol to Induce the Temporary Opening of the Blood-Brain Barrier with Short-Time Focused Ultrasound in Rats.Pharmaceutics · 2023Article
- Intelligent nanotherapeutic strategies for the delivery of CRISPR system.Acta pharmaceutica Sinica. B · 2023Review
- The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.Frontiers in immunology · 2023Review
- Glioblastoma-on-a-chip construction and therapeutic applications.Frontiers in oncology · 2023Review
- Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors.Current oncology (Toronto, Ont.) · 2022Review
- Review
- Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing.Journal of nanobiotechnology · 2022Review
- Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect.Journal of nanobiotechnology · 2022Review
- Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.Molecular brain · 2022Review
- Therapeutic Options in Neuro-Oncology.International journal of molecular sciences · 2022Review
- Making waves: how ultrasound-targeted drug delivery is changing pharmaceutical approaches.Materials advances · 2022Review
- Sonosensitive capsules for brain thrombolysis increase ischemic damage in a stroke model.Journal of nanobiotechnology · 2022Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Recent advances in molecular neurooncology provide unique opportunities for targeted molecular-based therapies. However, the blood-brain barrier (BBB) remains a major limitation to the delivery of tumor-specific therapies directed against aberrant signaling pathways in brain tumors. Given the dismal prognosis of patients with malignant brain tumors, novel strategies that overcome the intrinsic limitations of the BBB are therefore highly desirable. Focused ultrasound BBB disruption is emerging as a novel strategy for enhanced delivery of therapeutic agents into the brain via focal, reversible, and safe BBB disruption. This review examines the potential role and implications of focused ultrasound in molecular neurooncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.